Nivolumab recommended as a second-line treatment option for patients with two types of non-small-cell lung cancer
NICE draft guidance means patients with advanced squamous or non-squamous NSCLC will now be eligible for the second-line treatment on the NHS.
Published
Join OnMedica and benefit from:
- Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
- High-quality, evidence-based content developed by expert editors and clinicians
- Articles, quizzes, videos, visual summaries and more
- Regulatory alerts and round-up of medical journals
- New content added daily, so you know you’re always up to date
